Speaker: Dr. Mike Taussig is founder and CEO of Cambridge Protein Arrays Ltd., a European provider of large scale protein arrays and screening services for antibody validation, auto-antibody discovery and protein interactions.He was formerly head of the Protein Technology Group at The Babraham Institute, Cambridge, UK. His research experience and interests include structure and genetics of antibodies, display libraries, array design, cell-free protein expression and antibody crystallography. He is noted as co-inventor of ribosome display technology for in vitro selection of antibodies, and in situ protein array methods. He has coordinated several large scale European networking and research projects with the aim of establishing resources of antibodies and other affinity reagents for detection of the human proteome. He is the organizer of the biennial Alpbach workshops on Affinity Proteomics, a leading conference dealing with issues of antibody validation (www.affinityproteomicsalpbach.com). Dr. Taussig is also Editor-in-Chief of New Biotechnology, the official journal of the European Federation of Biotechnology.
Speaker: Fridtjof Lund-Johansen, MD, PhD, is head of the protein array group and flow cytometry core facility at Oslo University Hospital, Oslo, Norway. He started working with bead-based flow cytometric assays as a post-doctoral fellow at BD-biosciences and DNAX Institute in the mid-1990s. He is inventor of Microsphere Affinity Proteomics (MAP), which involves use of bead-based antibody arrays and flow cytometry to analyze biotinylated and size-separated proteins. MAP has been combined with polyacrylamide gel electrophoresis for an assay analogous to a “capture western blot” and with size exclusion chromatography for high-resolution analysis of protein complexes. Key features of MAP include parallel detection with thousands of antibodies and seamless integration with shotgun mass spectrometry (MS) and immunoprecipitation and MS for indirect and direct assessment of antibody specificity, respectively.
Dr. Simon Goodman moderates this webinar series.
